215 related articles for article (PubMed ID: 33859327)
21. Multiple karyotypic abnormalities in three cases of small cell variant of T-cell prolymphocytic leukemia.
Heinonen K; Mahlamäki E; Hämäläinen E; Nousiainen T; Mononen I
Cancer Genet Cytogenet; 1994 Nov; 78(1):28-35. PubMed ID: 7987802
[TBL] [Abstract][Full Text] [Related]
22. Recurrence of T-Cell Prolymphocytic Leukemia With a Rare Presentation as Diffuse Generalized Skin Lesion.
Wasifuddin M; Sabzposh H; Sun L; Wu R; Wang JC
J Investig Med High Impact Case Rep; 2023; 11():23247096231176223. PubMed ID: 37219076
[TBL] [Abstract][Full Text] [Related]
23. [T-cell prolymphocytic leukemia: potential diagnostic pitfalls].
Dessart P; Lemaire P; Le Dû K; Sandrini J; Prophette B; Maillard H
Ann Dermatol Venereol; 2014 Dec; 141(12):777-81. PubMed ID: 25433931
[TBL] [Abstract][Full Text] [Related]
24. Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemia.
Hasanali ZS; Saroya BS; Stuart A; Shimko S; Evans J; Vinod Shah M; Sharma K; Leshchenko VV; Parekh S; Loughran TP; Epner EM
Sci Transl Med; 2015 Jun; 7(293):293ra102. PubMed ID: 26109102
[TBL] [Abstract][Full Text] [Related]
25. [Cerebriform variant type of T cell prolymphocytic leukemia: Report of one case].
Peña C; Valladares X; Soto C; Encina A; Marinov N; Undurraga MS; Cabrera ME
Rev Med Chil; 2016 Jan; 144(1):124-8. PubMed ID: 26998991
[TBL] [Abstract][Full Text] [Related]
26. Recurrent loss, but lack of mutations, of the SMARCB1 tumor suppressor gene in T-cell prolymphocytic leukemia with TCL1A-TCRAD juxtaposition.
Bug S; Dürig J; Oyen F; Klein-Hitpass L; Martin-Subero JI; Harder L; Baudis M; Arnold N; Kordes U; Dührsen U; Schneppenheim R; Siebert R
Cancer Genet Cytogenet; 2009 Jul; 192(1):44-7. PubMed ID: 19480937
[TBL] [Abstract][Full Text] [Related]
27. T-cell prolymphocytic leukemia with a novel translocation (6;11)(q21;q23).
Wong KF; Chan JK; Sin VC
Cancer Genet Cytogenet; 1999 Jun; 111(2):149-51. PubMed ID: 10347553
[TBL] [Abstract][Full Text] [Related]
28. T-cell prolymphocytic leukemia: Review of an entity and its differential diagnostic considerations.
Frater JL
Int J Lab Hematol; 2020 Jun; 42 Suppl 1():90-98. PubMed ID: 32543075
[TBL] [Abstract][Full Text] [Related]
29. Current understandings on T-cell prolymphocytic leukemia and its association with TCL1 proto-oncogene.
Sun S; Fang W
Biomed Pharmacother; 2020 Jun; 126():110107. PubMed ID: 32247279
[TBL] [Abstract][Full Text] [Related]
30. [Research Advances of Genetics, Diagnosis and Treatment of T-cell Prolymphocytic Leukemia--Review].
Lai MF; Li F
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Dec; 29(6):1977-1981. PubMed ID: 34893145
[TBL] [Abstract][Full Text] [Related]
31. Noncanonical Function of AGO2 Augments T-cell Receptor Signaling in T-cell Prolymphocytic Leukemia.
Braun T; Stachelscheid J; Bley N; Oberbeck S; Otte M; Müller TA; Wahnschaffe L; Glaß M; Ommer K; Franitza M; Gathof B; Altmüller J; Hallek M; Auguin D; Hüttelmaier S; Schrader A; Herling M
Cancer Res; 2022 May; 82(9):1818-1831. PubMed ID: 35259248
[TBL] [Abstract][Full Text] [Related]
32. Unusually indolent T-cell prolymphocytic leukemia associated with a complex karyotype: is this T-cell chronic lymphocytic leukemia?
Soma L; Cornfield DB; Prager D; Nowell P; Bagg A
Am J Hematol; 2002 Nov; 71(3):224-6. PubMed ID: 12410582
[TBL] [Abstract][Full Text] [Related]
33. A case report of T cell prolymphocytic leukemia and Kaposi sarcoma and a review of T cell prolymphocytic leukemia.
Paul RN; Alizadeh L; Ajayi OI; Karpurapu H; Ganesan C; Taddesse-Heath L; Aggarwal A
Acta Haematol; 2012; 127(4):235-43. PubMed ID: 22517037
[TBL] [Abstract][Full Text] [Related]
34. Fluorescent BAT-25 and BAT-26 analysis of T cell prolymphocytic leukaemia.
Bradshaw PS; Hamoudi R; Min T; Catovsky D; Houlston RS; Yuille MR
Leukemia; 1999 Dec; 13(12):2104-6. PubMed ID: 10602436
[TBL] [Abstract][Full Text] [Related]
35. Mutations in PIGA cause a CD52-/GPI-anchor-deficient phenotype complicating alemtuzumab treatment in T-cell prolymphocytic leukemia.
Johansson P; Klein-Hitpass L; Röth A; Möllmann M; Reinhardt HC; Dührsen U; Dürig J
Eur J Haematol; 2020 Dec; 105(6):786-796. PubMed ID: 32875608
[TBL] [Abstract][Full Text] [Related]
36. Immunophenotypic characterization of T-cell prolymphocytic leukemia.
Chen X; Cherian S
Am J Clin Pathol; 2013 Nov; 140(5):727-35. PubMed ID: 24124154
[TBL] [Abstract][Full Text] [Related]
37. Comparison of clinicopathological characteristics between T-cell prolymphocytic leukemia and peripheral T-cell lymphoma, not otherwise specified.
Kawamoto K; Miyoshi H; Yanagida E; Yoshida N; Kiyasu J; Kozai Y; Morikita T; Kato T; Suzushima H; Tamura S; Muta T; Kato K; Eto T; Seki R; Nagafuji K; Sone H; Takizawa J; Seto M; Ohshima K
Eur J Haematol; 2017 May; 98(5):459-466. PubMed ID: 28129454
[TBL] [Abstract][Full Text] [Related]
38. Prognostic significance of cytogenetic abnormalities in T-cell prolymphocytic leukemia.
Hu Z; Medeiros LJ; Fang L; Sun Y; Tang Z; Tang G; Sun T; Quesada AE; Hu S; Wang SA; Pei L; Lu X
Am J Hematol; 2017 May; 92(5):441-447. PubMed ID: 28194886
[TBL] [Abstract][Full Text] [Related]
39. Advances and Perspectives in the Treatment of T-PLL.
Braun T; von Jan J; Wahnschaffe L; Herling M
Curr Hematol Malig Rep; 2020 Apr; 15(2):113-124. PubMed ID: 32034661
[TBL] [Abstract][Full Text] [Related]
40. Chronic lymphatic leukemias of T and NK cell type.
Kingreen D; Siegert W
Leukemia; 1997 Apr; 11 Suppl 2():S46-9. PubMed ID: 9178839
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
